Amgen GmbH
- Headquarter: Vienna
- Federal states: Vienna
- Industry sectors: Pharmaceuticals, health & biotechnology
- Status: newly_certified
1995
Founding year
120
Employees
Amgen is one of the world’s leading companies in biotechnology. For over four decades, the company has been developing life-changing therapies based on modern biotechnological research. Founded in 1980 in a garage in Thousand Oaks, California, Amgen is now present in over 100 countries and employs around 27,000 people worldwide.
Thirty years ago, Amgen established its site in Austria. Since then, around 120 employees have been working in Vienna with the goal of improving patients’ lives through innovative therapies.
Amgen Austria stands for excellent research, strong partnerships in the healthcare sector, and a clear goal of advancing medical progress for patients.
Since 2025, Amgen Austria has been a bearer of the “Leitbetrieb Austria” quality seal, which certifies economic stability and social responsibility.
Products and services
Amgen Austria offers a broad portfolio of highly effective biotechnological medicines that target some of the most complex and challenging diseases of our time. The focus is on indications with high unmet medical need, where standard therapies are often insufficient – and innovation makes the crucial difference.
Amgen concentrates on serious and chronic conditions – for example, in oncology, cardiology, immunology, and bone health. With its BiTE® technology (Bispecific T-Cell Engager), Amgen has developed an innovative approach to selectively activating the immune system against cancer cells.
Rare diseases are also becoming an increasing focus. Although they affect relatively few patients, they pose a significant burden for those affected. In this area, Amgen is committed to targeted research and new therapeutic approaches.
In addition, Amgen develops biosimilars – high-quality biopharmaceutical imitation products – and actively engages in clinical research. Currently, more than 40 clinical studies are being conducted from the HUB in Austria across eight countries, with more than 20 of them in Austria. These studies make a vital contribution to the development of new active ingredients and to the safety of future therapies.
